140 related articles for article (PubMed ID: 36976352)
1. Decreased expression of prolyl hydroxylase 1 is associated with poor prognosis in colorectal cancers.
Melling N; Grass J; Reeh M; Tachezy M; Blessmann M; Izbicki JR; Grupp K
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7579-7585. PubMed ID: 36976352
[TBL] [Abstract][Full Text] [Related]
2. Low expression of prolyl hydroxylase 2 is associated with tumor grade and poor prognosis in patients with colorectal cancer.
Xie G; Zheng L; Ou J; Huang H; He J; Li J; Pan F; Liang H
Exp Biol Med (Maywood); 2012 Jul; 237(7):860-6. PubMed ID: 22802519
[TBL] [Abstract][Full Text] [Related]
3. Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer.
Rawluszko AA; Bujnicka KE; Horbacka K; Krokowicz P; Jagodziński PP
BMC Cancer; 2013 Nov; 13():526. PubMed ID: 24195777
[TBL] [Abstract][Full Text] [Related]
4. Gene Expression Levels of the Prolyl Hydroxylase Domain Proteins
Koren A; Rijavec M; Krumpestar T; Kern I; Sadikov A; Čufer T; Korošec P
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065840
[TBL] [Abstract][Full Text] [Related]
5. The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
Fox SB; Generali D; Berruti A; Brizzi MP; Campo L; Bonardi S; Bersiga A; Allevi G; Milani M; Aguggini S; Mele T; Dogliotti L; Bottini A; Harris AL
Breast Cancer Res; 2011 Feb; 13(1):R16. PubMed ID: 21291529
[TBL] [Abstract][Full Text] [Related]
6. Loss of H2Bub1 Expression is Linked to Poor Prognosis in Nodal Negative Colorectal Cancers.
Melling N; Grimm N; Simon R; Stahl P; Bokemeyer C; Terracciano L; Sauter G; Izbicki JR; Marx AH
Pathol Oncol Res; 2016 Jan; 22(1):95-102. PubMed ID: 26347467
[TBL] [Abstract][Full Text] [Related]
7. Loss of RNA-binding motif protein 3 expression is associated with right-sided localization and poor prognosis in colorectal cancer.
Melling N; Simon R; Mirlacher M; Izbicki JR; Stahl P; Terracciano LM; Bokemeyer C; Sauter G; Marx AH
Histopathology; 2016 Jan; 68(2):191-8. PubMed ID: 25922889
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Correlation Between MFG-E8 Expression Level and Colorectal Cancer.
Jia M; Yao H; Chen C; Wang Y; Wang H; Cui T; Zhu J
Arch Med Res; 2017 Apr; 48(3):270-275. PubMed ID: 28923329
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer.
Jia X; Shanmugam C; Paluri RK; Jhala NC; Behring MP; Katkoori VR; Sugandha SP; Bae S; Samuel T; Manne U
Oncotarget; 2017 Mar; 8(12):20198-20212. PubMed ID: 28423626
[TBL] [Abstract][Full Text] [Related]
10. Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
Lee YC; Su CY; Lin YF; Lin CM; Fang CY; Lin YK; Hsiao M; Chen CL
Oncotarget; 2017 Feb; 8(7):12120-12132. PubMed ID: 28076332
[TBL] [Abstract][Full Text] [Related]
11. Podocalyxin is a marker of poor prognosis in colorectal cancer.
Kaprio T; Fermér C; Hagström J; Mustonen H; Böckelman C; Nilsson O; Haglund C
BMC Cancer; 2014 Jul; 14():493. PubMed ID: 25004863
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase 10, a novel prognostic marker in colorectal cancer.
Park HS; Yeo HY; Chang HJ; Kim KH; Park JW; Kim BC; Baek JY; Kim SY; Kim DY
Yonsei Med J; 2013 Nov; 54(6):1362-9. PubMed ID: 24142639
[TBL] [Abstract][Full Text] [Related]
13. Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer.
Lee JL; Roh SA; Kim CW; Kwon YH; Ha YJ; Kim SK; Kim SY; Cho DH; Kim YS; Kim JC
World J Gastroenterol; 2019 Mar; 25(11):1341-1354. PubMed ID: 30918427
[TBL] [Abstract][Full Text] [Related]
14. Tumor sidedness is not an independent prognostic marker of colorectal cancer patients undergoing curative resection: A retrospective cohort study.
Chan JCY; Diakos CI; Engel A; Chan DLH; Pavlakis N; Gill A; Clarke SJ
PLoS One; 2019; 14(6):e0218207. PubMed ID: 31188892
[TBL] [Abstract][Full Text] [Related]
15. CILP2 overexpression correlates with tumor progression and poor prognosis in patients with colorectal cancer in The Cancer Genome Atlas (TCGA) study.
Huang F; Peng Y; Ye Q; Chen J; Li Y; Liu S; Xu Y; Huang L
World J Surg Oncol; 2020 Oct; 18(1):274. PubMed ID: 33099318
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
[TBL] [Abstract][Full Text] [Related]
17. The role of tumor budding in colorectal adenocarcinoma: Possible involvement of the intestinal cancer stem cell marker Lgr5.
Sadek SA; A Rehim DM; Fatima S
Indian J Pathol Microbiol; 2020; 63(1):32-37. PubMed ID: 32031119
[TBL] [Abstract][Full Text] [Related]
18. High expression of meningioma 1 is correlated with reduced survival rates in colorectal cancer patients.
Ho YJ; Liu FC; Chang J; Shi B; Yeh KT; Lin YM; Lu JW
Acta Histochem; 2019 Jul; 121(5):628-637. PubMed ID: 31133374
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of chemerin expression in colorectal cancer: A detailed analysis based on histological components and meta-analysis.
Oh IH; Pyo JS; Min KW; Kim OZ; Son BK
Pathol Res Pract; 2023 Nov; 251():154876. PubMed ID: 37898040
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival.
Andersen S; Donnem T; Stenvold H; Al-Saad S; Al-Shibli K; Busund LT; Bremnes RM
PLoS One; 2011; 6(8):e23847. PubMed ID: 21887331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
